Company Overview
Snapshot
Founded in January 2023, NucleoTech operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing advanced drug delivery systems for brain conditions.
Business overview
NucleoTech is a Health Tech & Life Sciences company focused on overcoming the limitations of drug delivery to the brain, particularly the challenge posed by the Blood Brain Barrier (BBB). The company develops specialized carriers, utilizing nanobodies (Single Domain Antibodies), to shuttle various drug classes, including biologics and RNA drugs, across the BBB via Receptor-Mediated Transcytosis. NucleoTech's technology aims to enable more effective treatment for brain conditions by allowing therapeutic molecules to reach the brain, serving the pharmaceutical and life sciences industries.
Log in to access full profile ›Company Intelligence Q&A
- What is NucleoTech's primary focus?
- NucleoTech is focused on developing effective drug delivery solutions to the brain, specifically addressing the challenge of the Blood Brain Barrier (BBB) which limits therapeutic access to the brain.
- What technology does NucleoTech utilize for drug delivery?
- NucleoTech utilizes nanobodies, also known as Single Domain Antibodies, as carrier molecules. These nanobodies leverage the BBB's own transfer mechanisms to facilitate the delivery of therapeutic molecules into the brain through Receptor-Mediated Transcytosis.
- What types of drugs can NucleoTech's technology deliver?
- NucleoTech's carriers are designed to deliver a variety of drug classes across the Blood Brain Barrier, including biologics and RNA drugs.
- When was NucleoTech founded?
- NucleoTech was founded in January 2023.
- What is NucleoTech's business model?
- NucleoTech operates on a B2B business model, serving the pharmaceutical and life sciences industries with its drug delivery technology.